Full Text View
Tabular View
No Study Results Posted
Related Studies
Safety and Immune Response Study of High-Dose Canarypox ALVAC-HIV Vaccine in Healthy, HIV Uninfected Adults
This study has been completed.
Study NCT00027261   Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 29, 2001   Last Updated: August 19, 2008   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
HIV Seronegativity
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Infection
More general conditions related to this trial
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
ALVAC(2)120(B,MN)GNP (vCP1452)
Sponsors listed in this trial
National Institute of Allergy and Infectious Diseases (NIAID)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services